2020 was an unprecedented year as the world faced the unexpected and rapid spread of coronavirus. As the pandemic extends into 2021, we have been witnessing specific new variants spreading rapidly in the United Kingdom, South Africa and Brazil.
These new variants will however not impact the performance of our molecular assays Amplidiag COVID-19, nor Novodiag COVID-19, which utilise targets for N gene and Orf1ab. The new coronavirus variants potentially have an impact on assays using the S protein as a target, which is not the case for Mobidiag tests. At Mobidiag, it is part of our routine post-market surveillance to monitor for new coronavirus variants and developments to ensure that the performance of our assays is always suitable for the market.
If you have any questions, please do not hesitate to contact us:
By email: firstname.lastname@example.org
+358 10 5050 770
+44 333 305 7506
+33 1 55 25 17 00